Amgen (AMGN) news
Recent news
Dow Jones unofficially closes up 189.88 points, or 0.37%, at 51,844.83
The Dow Jones Industrial Average (DJIA) rose 189.88 points, or 0.37%, to close at 51,844.83 on Friday, reflecting modest gains amid ongoing market adjustments. The index, which tracks the performance of 30 large, publicly traded U.S. companies, has undergone recent changes to its composition, with…
AInvest Wire · 8h agoAmgen Inc: Guggenheim cuts target price to $378 from $388
Guggenheim Securities has revised its price target for Amgen Inc (AMGN), reducing it to $378 from a previous level of $388, according to recent analyst updates. The adjustment reflects a reassessment of the biopharmaceutical company’s near-term outlook, though the firm has not indicated a change in…
AInvest Wire · 14h agoGen Ilac - Granted exclusive rights for registration, sales, marketing, and distribution
Gen Ilac, a pharmaceutical company, has recently been granted exclusive rights for the registration, sales, marketing, and distribution of a product, marking a strategic development in its business operations. This move aligns with broader industry trends where companies seek to expand their market…
AInvest Wire · 19h agoAmgen Inc: UBS raises target price to $470 from $430
UBS has revised its price target for Amgen Inc (AMGN), raising it to $470 from $430, reflecting a positive reassessment of the company’s outlook [1]. The adjustment follows recent developments in Amgen’s portfolio and market positioning. Analysts at UBS highlighted the company’s progress in key…
AInvest Wire · 3d agoBio-pharmaceutical stocks fell in intraday trading, with Eli Lilly down 4.73%, Amgen falling 2.93% and Merck sliding 2.33%.
Bio-pharmaceutical stocks experienced a decline in intraday trading on Monday, with several major players posting notable losses. Eli Lilly shares dropped 4.73%, while Amgen fell 2.93%. Merck also saw a decline, with its stock sliding 2.33% . The downward movement reflects broader market volatility…
AInvest Wire · 4d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.